Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Future shares fall on revenue growth caution; H1 profits jump

(Sharecast News) - Future shares fell on Friday as the specialist publisher cautioned that it expected a low single-digit decline in full-year organic revenue amid economic uncertainty. The company, which owns the Go.Compare price comparison website, posted a 21% increase in pre-tax profit to £56.6m for the six months to March. Operating profit rose 8% to £69.1m, driven by lower exceptional costs, and it also a new £55m share buyback.

Revenue fell 3% to £378.4m, as growth in the first quarter was offset by uncertain macroeconomic sentiment in March, impacting US direct advertising, although this recovered in April.

"At this stage, given ongoing macroeconomic uncertainty, the group believes it is prudent to adopt a more cautious view on the second half and expects a low single-digit decline in full-year organic revenue," the company said, adding that forex headwinds were also an issue.

In the business-to-consumer division - Future's largest - organic revenue was flat in the period with "excellent" performance in magazines offset by decline in media, driven by digital advertising.

Revenues at Go.Compare fell 1% as the volume of car insurance quotes decreased, although revenue from non-automotive insurance quotes surged by10%.

Future said it continued to expect to deliver a stable adjusted operating margin of 28% alongside continued strong cash generation.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.